GlassScriptPhysician profile
John T Crawford
NPI 1285629832
$3,256.78
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $640 · 2020: $793 · 2021: $1,404 · 2022: $419.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $978.65 | 2019-2022 | |
| Amgen INC. | $415.05 | 2019-2022 | |
| Abbvie INC. | $314.19 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $193.28 | 2019-2021 | |
| Amarin Pharma, INC. | $185.22 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $126.89 | 2019-2021 | |
| Mylan Specialty L.P. | $120.00 | 2019 | |
| Abbott Laboratories | $102.67 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $101.84 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.07 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.28 | 2020-2022 | |
| Allergan, INC. | $68.32 | 2019-2020 | |
| Lilly USA, LLC | $61.27 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $58.28 | 2021 | |
| Glaxosmithkline, LLC. | $44.44 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $43.58 | 2022 | |
| Pfizer INC. | $40.49 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.13 | 2020-2021 | |
| Astellas Pharma US INC | $33.14 | 2021 | |
| Clarus Therapeutics INC. | $31.38 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.94 | 2022 | |
| Sanofi Pasteur INC. | $15.80 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.47 | 2019 | |
| Antares Pharma, INC. | $14.36 | 2022 | |
| Hologic Sales and Service, LLC | $13.92 | 2021 | |
| Horizon Therapeutics Plc | $13.82 | 2021 | |
| Merck Sharp & Dohme LLC | $13.17 | 2021 | |
| Cranial Technologies, INC | $12.43 | 2022 | |
| Eisai INC. | $11.70 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.